Alkermes' orexin agonist shows early promise in ADHD trial

Alkermes reported that its orexin agonist demonstrated potential efficacy in treating ADHD in an early-stage trial, marking a novel mechanism for the condition. The data are preliminary and unverified, but if confirmed, could offer a new therapeutic class for ADHD. The market impact is limited to the company and sector, with no immediate macro-directional signal.